Novelties in the treatment of heart failure
Authors:
Filip Souček 1; Jan Novák 2
Authors‘ workplace:
I. interní kardio-angiologická klinika LF MU a FN u sv. Anny v Brně
1; II. interní klinika LF MU a FN U sv. Anny v Brně
2
Published in:
Vnitř Lék 2017; 63(4): 255-264
Category:
Reviews
Overview
Heart failure (HF) is a complex clinical syndrome which is manifested by characteristic symptoms and objective signs of cardiac insufficiency. The incidence of HF, particularly its chronic form, is estimated 0.4–2 % in the central and western Europe, with an increase in higher age groups, affecting 10–20 % of the population aged over 80. With respect to its growing incidence and prevalence, novel modalities of pharmacological and non-pharmacological treatment are being developed in order to improve quality of life and survival of the affected patients. This review based on up-to-date guidelines focuses in the first part on brief description of the possibilities of diagnosing heart failure, including the novelties arising out from the latest clinical and preclinical studies (such as soluble ST2, FSTL1, etc), further it concentrates on innovations in pharmacological treatment of chronic (ivabradine, ARNI, gliflozins) and acute (ularitide, serelaxin, nesiritide) HF. The last part provides an overview of available non-pharmacological HF therapeutics options (modulation of cardiac contraction, influencing the activity of sympathetic and parasympathetic nervous systems and permanent and temporary device support).
Key words:
ARNI – ECMO – gliflozins – heart failure – modulation of sympathetic and parasympathetic nervous systems – sacubitril-valsartan – therapy
Sources
1. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007; 93(9): 1137–1146.
2. Redfield MM, Jacobsen SJ, Burnett JC et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289(2): 194–202.
3. Bleumink GS, Knetsch AM, Sturkenboom MCJM et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 2004; 25(18): 1614–1619.
4. Ceia F, Fonseca C, Mota T et al. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail 2002; 4:(4) 531–539.
5. Levy D, Kenchaiah S, Larson MG et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347(18): 1397–1402.
6. Roger VL, Weston SA, Redfield MM et al. Trends in heart failure incidence and survival in a community-based population. JAMA 2004; 292(3): 344–350.
7. van Riet EES, Hoes AW, Limburg A et al. Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. Eur J Heart Fail 2014; 16(7): 772–777. Dostupné z DOI: <http://dx.doi.org/10.1002/ejhf.110>.
8. Maggioni AP, Dahlström U, Filippatos G et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2013; 15(7): 808–817. Dostupné z DOI: <http://dx.doi.org/10.1093/eurjhf/hft050>.
9. Pocock SJ, Wang D, Pfeffer MA et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006; 27(1): 65–75.
10. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18(8): 891–975. Dostupné z DOI: <http://dx.doi.org/10.1002/ejhf.592>.
11. Málek F, Vondráková D, Neužil P. Význam stanovení solubilního receptoru ST2 v diagnostice a prognostické stratifikaci pacientů se srdečním selháním. Vnitř Lék 2015; 61(12): 1039–1041.
12. Chen A, Hou W, Zhang Y et al. Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis. Int J Cardiol 2015; 182: 168–170. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijcard.2014.12.137>.
13. Vegter EL, Schmitter D, Hagemeijer Y et al. Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. Int J Cardiol 2016; 224: 231–239. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijcard.2016.09.010>.
14. Ovchinnikova ES, Schmitter D, Vegter EL et al. Signature of circulating microRNAs in patients with acute heart failure. Eur J Heart Fail 2016; 18(4): 414–423. Dostupné z DOI: <http://dx.doi.org/10.1002/ejhf.332>.
15. Balling L, Gustafsson F. Copeptin in Heart Failure. Adv Clin Chem 2016; 73: 29–64. Dostupné z DOI: <http://dx.doi.org/10.1016/bs.acc.2015.10.006>.
16. Yuyun MF, Narayan HK, Ng LL. Prognostic significance of adrenomedullin in patients with heart failure and with myocardial infarction. Am J Cardiol 2015; 115(7): 986–991. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2015.01.027>.
17. El-Armouche A, Ouchi N, Tanaka K et al. Follistatin-like 1 in chronic systolic heart failure: a marker of left ventricular remodeling. Circ Heart Fail 2011; 4(5): 621–627. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCHEARTFAILURE.110.960625>.
18. Tanaka K, Valero-Muñoz M, Wilson RM et al. Follistatin like 1 Regulates Hypertrophy in Heart Failure with Preserved Ejection Fraction. JACC Basic Transl Sci 2016; 1(4): 207–221.
19. van Rooij E. Cardiac Repair after Myocardial Infarction. N Engl J Med 2016; 374(1): 85–87.Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMcibr1512011>.
20. Mazurek JA, Jessup M. Understanding Heart Failure. Heart Fail Clin 2017; 13(1): 1–19. Dostupné z DOI: <http://dx.doi.org/10.1016/j.hfc.2016.07.001>.
21. Lechat P, Hulot JS, Escolano S et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001; 103(10): 1428–1433.
22. Ragueneau I, Laveille C, Jochemsen R et al. Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther 1998; 64(2): 192–203.
23. Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376(9744): 875–885. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(10)61198–1>.
24. Böhm M, Borer J, Ford I et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013; 102(1): 11–22. Dostupné z DOI: <http://dx.doi.org/10.1007/s00392–012–0467–8>.
25. Swedberg K, Komajda M, Böhm M et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol 2012; 59(22): 1938–1945. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2012.01.020>.
26. Zannad F, McMurray JJV, Krum H et al. [EMPHASIS-HF Study Group]. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364(1): 11–21.Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1009492>.
27. [CONSENSUS Trial Study Group]. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316(23): 1429–1435.
28. [The SOLVD Investigators]. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325(5): 293–302.
29. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273(18): 1450–1456. Erratum in JAMA 1995; 274(6): 462.
30. Vítovec J, Špinar J, Špinarová L. Inhibice systému renin-angiotenzin-aldosteron u srdečního selhání aneb od obecného souhlasu (CONSENSUS) po vzorec myšlení (PARADIGM-HF). Vnitř Lék 2015; 61(5): 470–474.
31. Del Ry S, Cabiati M, Clerico A. Natriuretic peptide system and the heart. In: Granata R, Isgaard J (eds). Cardiovascular Issues in Endocrinology. Front Horm Res 43: 134–143. Karger; Basel 2014. ISBN: 978–3-318–02673–3. e-ISBN: 978–3-318–02674–0Dostupné z DOI: <http://dx.doi.org/10.1159/000360597>.
32. Uijl E, Roksnoer LCW, Hoorn EJ et al. From ARB to ARNI in Cardiovascular Control. Curr Hypertens Rep 2016; 18(12): 86.
33. Packer M, Califf RM, Konstam MA et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106(8): 920–926.
34. Kostis JB, Packer M, Black HR et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004; 17(2): 103–111.
35. McMurray JJV, Packer M, Desai AS et al. [PARADIGM-HF Investigators and Committees]. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371(11): 993–1004. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1409077>.
36. Zinman B, Wanner C, Lachin JM et al. [EMPA-REG OUTCOME Investigators]. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22): 2117–2128. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1504720>.
37. Murín J. Sú niektoré antidiabetiká aj liekmi na srdcové zlyhávanie? Vnitř Lék 2016; 62(4): 322–328.
38. Ghosh RK, Bandyopadhyay D, Hajra A et al. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies. Int J Cardiol 2016; 212: 29–36. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijcard.2016.02.134>.
39. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362(9386): 777–781.
40. Massie BM, Carson PE, McMurray JJ et al. [I-PRESERVE Investigators]. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359(23): 2456–2467. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0805450>.
41. Pitt B, Pfeffer MA, Assmann SF et al. [TOPCAT Investigators]. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370(15): 1383–1392. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1313731>.
42. Gregorová Z, Meluzín J, Špinarová L. Co je nového v srdečním selhání se zachovalou ejekční frakcí levé komory za posledních pět let? Vnitř Lék 2014; 60(7–8): 586–594.
43. O’Connor CM, Starling RC, Hernandez AF et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365(1): 32–43. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1100171>. Erratum in N Engl J Med 2011; 365(8): 773.
44. Teerlink JR, Cotter G, Davison BA et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013; 381(9860): 29–39. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(12)61855–8>.
45. Anker SD, Ponikowski P, Mitrovic V et al. Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. Eur Heart J 2015; 36(12): 715–723. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehu484>.
46. Packer M, Holcomb R, Abraham WT et al. Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure. Eur J Heart Fail 2016 (on-line). Dostupné z DOI: <http://dx.doi.org/10.1002/ejhf.698>.
47. Burke MC, Gold MR, Knight BP et al. Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry. J Am Coll Cardiol 2015; 65(16): 1605–1615. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2015.02.047>.
48. Bardy GH, Smith WM, Hood MA et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med 2010; 363(1): 36–44. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0909545>.
49. Opreanu M, Wan C, Singh V et al. Wearable cardioverter-defibrillator as a bridge to cardiac transplantation: A national database analysis. J Heart Lung Transplant 2015; 34(10): 1305–1309. Dostupné z DOI: <http://dx.doi.org/10.1016/j.healun.2015.04.004>.
50. Chung MK, Szymkiewicz SJ, Shao M et al. Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival. J Am Coll Cardiol 2010; 56(3): 194–203. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2010.04.016>.
51. Zweerink A, Wu L, de Roest GJ et al. Improved patient selection for cardiac resynchronization therapy by normalization of QRS duration to left ventricular dimension. Europace 2016. pii: euw265. Dostupné z DOI: <https://doi.org/10.1093/europace/euw265>.
52. Carità P, Corrado E, Pontone G et al. Non-responders to cardiac resynchronization therapy: Insights from multimodality imaging and electrocardiography. A brief review. Int J Cardiol 2016; 225: 402–407. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijcard.2016.09.037>.
53. Ruschitzka F, Abraham WT, Singh JP et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med 2013; 369(15): 1395–1405. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1306687>.
54. Cleland JG, Abraham WT, Linde C et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J 2013; 34(46): 3547–3556. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/eht290>.
55. Kadish A, Nademanee K, Volosin K et al. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. Am Heart J 2011; 161(12): 329–337. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ahj.2010.10.025>. Erratum in Am Heart J 2011; 161(6): 1220.
56. Singh JP, Kandala J, Camm AJ. Non-pharmacological modulation of the autonomic tone to treat heart failure. Eur Heart J 2014; 35(2): 77–85.Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/eht436>.
57. Abraham WT, Zile MR, Weaver FA et al. Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. JACC Heart Fail 2015; 3(6): 487–496. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jchf.2015.02.006>.
58. Chakravarthy K, Chaudhry H, Williams K et al. Review of the Uses of Vagal Nerve Stimulation in Chronic Pain Management. Curr Pain Headache Rep 2015; 19(12): 54.Dostupné z DOI: <http://dx.doi.org/10.1007/s11916–015–0528–6>.
59. Zannad F, Ferrari GMD, Tuinenburg AE et al. Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. Eur Heart J 2015; 36(7): 425–433. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehu345.
60. Zipes DP, Neuzil P, Theres H et al. Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure: The DEFEAT-HF Study. JACC Heart Fail 2016; 4(2): 129–136. Dostupné z DOI: 61. Patel HC, Rosen SD, Hayward C et al. Renal denervation in heart failure with preserved ejection fraction (RDT-PEF): a randomized controlled trial. Eur J Heart Fail 2016; 18(6): 703–712. Dostupné z DOI: <http://dx.doi.org/10.1002/ejhf.502>.
62. Halushka MK, Mitchell RN, Padera RF. Heart failure therapies: new strategies for old treatments and new treatments for old strategies. Cardiovasc Pathol 2016; 25(6): 503–511. Dostupné z DOI: <http://dx.doi.org/10.1016/j.carpath.2016.08.008>.
63. Sajgalik P, Grupper A, Edwards BS et al. Current Status of Left Ventricular Assist Device Therapy. Mayo Clin Proc 2016; 91(7): 927–940. Dostupné z DOI: <http://dx.doi.org/10.1016/j.mayocp.2016.05.002>.
64. Prinzing A, Herold U, Berkefeld A et al. Left ventricular assist devices-current state and perspectives. J Thorac Dis 2016; 8(8): E660-E666. Dostupné z DOI: <http://dx.doi.org/10.21037/jtd.2016.07.13>.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2017 Issue 4
Most read in this issue
- Relapsing autoimmune pancreatitis type 1: case report
- Controversies around QALYs
- AT1 blockers – comparability with ACE inhibitors
- Novelties in the treatment of heart failure